We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
  • Gowling WLG
  • Canada
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998


Apotex v Sanofi, case management directions on the late disclosure of documents or information
  • Gowling WLG
  • Canada
  • May 21 2010

Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question


Merck-Frosst-Schering Pharma GP v. Canada (Health) (2010 FC 933)
  • Gowling WLG
  • Canada
  • October 27 2010

Merck-Frosst (“Merck”) applied for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for its generic version of Ezetimibe


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope
  • Gowling WLG
  • Canada, United Kingdom
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL


Impacts of the Amazon.com decisions on medical use claims in Canada
  • Gowling WLG
  • Canada
  • July 13 2012

Methods of medical treatment and surgery are not statutory subject matter in Canada


Apotex v Lundbeck, motion to strike pleadings and for security for costs, escitalopram, August 5, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

In earlier PMNOC proceedings, Lundbeck successfully obtained an order prohibiting the Minister from issuing a Notice of Compliance to Apotex in respect of its escitalopram product


Apotex v. Janssen-Ortho, motion to vary order of Federal Court of Appeal, levofloxacin, August 20, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

Apotex filed a Notice of Allegation alleging that a particular patent licensed by Janssen-Ortho was invalid and not infringed